Compare BWFG & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWFG | PEPG |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.0M | 317.6M |
| IPO Year | N/A | 2022 |
| Metric | BWFG | PEPG |
|---|---|---|
| Price | $46.95 | $6.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $53.00 | $10.80 |
| AVG Volume (30 Days) | 61.0K | ★ 625.0K |
| Earning Date | 01-21-2026 | 02-23-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ 88.52 | N/A |
| EPS | ★ 3.66 | N/A |
| Revenue | ★ $94,282,000.00 | N/A |
| Revenue This Year | $68.08 | N/A |
| Revenue Next Year | $13.72 | N/A |
| P/E Ratio | $12.30 | ★ N/A |
| Revenue Growth | ★ 30.93 | N/A |
| 52 Week Low | $26.39 | $0.88 |
| 52 Week High | $51.54 | $7.80 |
| Indicator | BWFG | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 63.32 |
| Support Level | $44.95 | $6.28 |
| Resistance Level | $47.10 | $7.80 |
| Average True Range (ATR) | 1.34 | 0.50 |
| MACD | -0.47 | 0.13 |
| Stochastic Oscillator | 31.87 | 60.37 |
Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.